Bicara Therapeutics Inc. Research and Development Expense
Bicara Therapeutics Inc. (BCAX) reported Research and Development Expense of $33.00 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-10
- Bicara Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $33.00M, a 107.55% increase year-over-year.
- Bicara Therapeutics Inc. research and development expense for the quarter ending 2025-06-30 was $24.80M, a 56.96% increase year-over-year.
- Bicara Therapeutics Inc. research and development expense for the quarter ending 2025-03-31 was $34.30M, a 185.83% increase year-over-year.
- Bicara Therapeutics Inc. research and development expense for the quarter ending 2024-12-31 was $19.90M, a 89.52% increase year-over-year.
- Bicara Therapeutics Inc. research and development expense for fiscal 2024 was $63.60M, a 107.84% increase from fiscal 2023.
- Bicara Therapeutics Inc. research and development expense for fiscal 2023 was $30.60M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $33.00M 10-Q · filed 2025-11-10 | $57.80M derived: sum of 2 quarters · filed 2025-11-10 | $92.10M 10-Q · filed 2025-11-10 | $112.00M derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | $24.80M 10-Q · filed 2025-08-12 | $59.10M 10-Q · filed 2025-08-12 | $79.00M derived: sum of 3 quarters · filed 2025-08-12 | $94.90M derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-03-31 | $34.30M 10-Q · filed 2025-05-13 | $54.20M derived: sum of 2 quarters · filed 2025-05-13 | $70.10M derived: sum of 3 quarters · filed 2025-11-10 | $85.90M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-12-31 | $19.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $35.80M derived: sum of 2 quarters · filed 2025-11-10 | $51.60M derived: sum of 3 quarters · filed 2025-11-10 | $63.60M 10-K · filed 2025-03-27 |
| 2024-09-30 | $15.90M 10-Q · filed 2025-11-10 | $31.70M derived: sum of 2 quarters · filed 2025-11-10 | $43.70M 10-Q · filed 2025-11-10 | $54.20M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $15.80M 10-Q · filed 2025-08-12 | $27.90M 10-Q · filed 2025-08-12 | $38.30M derived: sum of 3 quarters · filed 2025-08-12 | $45.20M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $12.00M 10-Q · filed 2025-05-13 | $22.50M derived: sum of 2 quarters · filed 2025-05-13 | $29.40M derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $17.40M derived: sum of 2 quarters · filed 2025-03-27 | $30.60M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $6.90M 10-Q · filed 2024-11-12 | $20.10M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |